Catalyst
Slingshot members are tracking this event:
FDA's Oncologic Drugs Advisory Committee to Review Puma's (PBYI) New Drug Application for Neratinib in HER-2 Positive Breast Cancer
- Source Link:
- http://www.pumabiotechnology.com/pr20170417.html
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PBYI |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 17, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Oncologic Drugs Advisory Committee, New Drug Application, Neratinib, Her-2 Positive Breast Cancer
